TradingView

Key facts: Biogen Lecanemab SC, 3-Year Data; Needham Raises Target $256

June 30, 2026 GMT+8 15:13 TradingView

Biogen to present lecanemab updates at AAIC 2026: subcutaneous at‑home formulation data and three‑year LEADER real‑world results on use, safety and maintenance dosing in U.S. clini

Biogen to present lecanemab updates at AAIC 2026: subcutaneous at‑home formulation data and three‑year LEADER real‑world results on use, safety and maintenance dosing in U.S. clinics
Needham raised its price target for Biogen Inc. (BIIB) to $256.00 per share from $255.00, reflecting a $1 increase in the firm’s valuation for the stock.